JUN 03, 2021 7:30 AM PDT

Inhalable Anti-COVID Nanobodies Show Promising Results in Hamsters

WRITTEN BY: Tara Fernandez

Nanobodies are small fragments of monoclonal antibodies that from a therapeutic perspective are more stable and cheaper to produce. Researchers have shown for the first time that inhalable nanobodies against SARS-CoV-2 can prevent and treat severe COVID in a hamster model of the disease.

The immune systems of camels, dromedaries, llamas, and alpacas feature this unique miniature antibody, which has been of particular interest to researchers for their application as therapeutic biologics. While most antibodies have both heavy and light chains, nanobodies have only heavy chains, making them around a tenth of the size of a monoclonal antibody.

In the study, small inhaled doses of the experimental nanobody treatment called Nanobody-21, or PiN-21, neutralized the coronavirus in infected animals, reducing the number of infectious viral particles in their respiratory tracts by a million-fold. Additionally, breathing in PiN-21 also had a protective effect when the hamsters were administered the treatment at the time of the infection. Even ultra-low doses of the nanobody were found to be effective, shielding the animals against inflammation and damage to their respiratory tracts.

“Inhalation treatment quickly reverses animals’ weight loss after infection, decreases lung viral titers by 6 logs leading to drastically mitigated lung pathology, and prevents viral pneumonia,” wrote the authors.

Senior author of the study, Yi Shi said: “By using an inhalation therapy that can be directly administered to the infection site—the respiratory tract and lungs—we can make treatments more efficient.” 

“We are very excited and encouraged by our data suggesting that PiN-21 can be highly protective against severe disease and can potentially prevent human-to-human viral transmission.”

The physical characteristics of nanobodies make them particularly well suited to be delivered as aerosols—tiny particles that when breathed in, reach deep into the intricate lung structures. With their dual function as both a treatment and a prophylactic, nanobodies may represent an urgently-needed complementary approach to vaccination.

The research team, which consists of nanobody, infectious disease, and aerobiology experts, is continuing to explore PiN-21 as a potential clinical drug candidate.

 


Sources: University of Pittsburgh, Science Advances.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
JUL 13, 2021
Immunology
A Moment of COVID, A Lifetime of Immune Protection?
JUL 13, 2021
A Moment of COVID, A Lifetime of Immune Protection?
Does getting vaccinated, or having recovered from COVID, provide life-long protection against the coronavirus? Most like ...
AUG 10, 2021
Immunology
A Tapeworm Drug as a COVID Antiviral?
AUG 10, 2021
A Tapeworm Drug as a COVID Antiviral?
A study by researchers at the Scripps Research Institute looking into potential COVID-19 medications has revealed a surp ...
AUG 17, 2021
Immunology
Does Fasting Help Protect Against Infection?
AUG 17, 2021
Does Fasting Help Protect Against Infection?
Most people feeling under the weather, especially those with a fever, tend to lose their appetites. When recovering from ...
SEP 06, 2021
Microbiology
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
SEP 06, 2021
Imbokodo Trial Shows HIV Vaccine Candidate Isn't Effective Enough
HIV vaccines have remained elusive in part because the virus has a powerful ability to mutate, and there are so many str ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
Loading Comments...